Loncar China BioPharma ETF (CHNA)
| Assets | $15.05M |
| NAV | $37.62 |
| Expense Ratio | 0.79% |
| PE Ratio | n/a |
| Shares Out | 400,000 |
| Dividend (ttm) | $0.16 |
| Dividend Yield | 0.41% |
| Ex-Dividend Date | Dec 30, 2020 |
| 1-Year Return | - |
| Volume | 2,705 |
| Open | 37.58 |
| Previous Close | 37.62 |
| Day's Range | 37.30 - 37.64 |
| 52-Week Low | 29.11 |
| 52-Week High | 49.01 |
| Beta | 0.81 |
| Holdings | 67 |
| Inception Date | Aug 14, 2018 |
About CHNA
The investment seeks to track the performance, before fees and expenses, of the Loncar China BioPharma Index (the index). Under normal circumstances, at least 80% of the fund's total assets (exclusive of any collateral held from securities lending) will be invested in the component securities of the index or in depositary receipts representing such component securities. The index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China's pharmaceutical and biotech related industries. The fund is non-diversified.
Top 10 Holdings
23.35% of assets| Name | Symbol | Weight |
|---|---|---|
| Brii Biosciences Ltd Ordinary Shares | 2137.HK | 2.92% |
| CARsgen Therapeutics Holdings Ltd Ordinary Shares | 2171.HK | 2.61% |
| Hangzhou Tigermed Consulting Co Ltd Class H | N/A | 2.54% |
| BeiGene | BGNE | 2.52% |
| Pharmaron Beijing Co Ltd Ordinary Shares - Class H | N/A | 2.28% |
| Wuxi AppTec Co Ltd | N/A | 2.24% |
| Innovent Biologics Inc | 1801.HK | 2.09% |
| Sino Biopharmaceutical Ltd | 1177.HK | 2.07% |
| WuXi Biologics (Cayman) Inc | 2269.HK | 2.04% |
| Austar Lifesciences Ltd Shs Reg S | 6118.HK | 2.03% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 30, 2020 | $0.1546187 | Jan 4, 2021 |
| Dec 23, 2019 | $0.04024942 | Dec 26, 2019 |
News
Best-Performing ETF Areas of Last Week
Last week was slightly downbeat for Wall Street on talks of a capital gain tax hike with three big U.S. indexes remaining in the red.
4 China ETFs Beating S&P 500 in its Worst Week Since 2008
Check these China ETFs that beat the S&P 500 in the past week, which was U.S. equities?
Best Pharmaceutical ETFs for Q1 2020
The best pharmaceutical ETFs for Q1 2020 are KURE, CHIH, and CHNA.
Why These Chinese Sector ETFs Are Crushing S&P 500 in 2019
Policy easing in the Chinese economy, cooling trade tensions with the United States and Beijing's efforts for more urbanization have boosted these sector ETFs in 2019.